[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"French Africa Pediatric Oncology Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":137},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,60,78,97,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100470562","thereapeutic-recommendantion-for-children-with-a-hodgkin-lymphoma-100470562",false,"NCT05407480","Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma","Therapeutic Recommendations for Children Registered in the RFAOP Register and With a Hodgkin Lymphoma","GFAOPLH2019","Inclusion Criteria:\n\nunder 18 years of age at diagnosis\n\n* suffering from \"classical\" Hodgkin's disease according to the WHO classification.\n* with no history of hematological malignancies or constitutional or acquired immune deficiencies\n\nExclusion Criteria:\n\n* Over 18 years of age at diagnosis\n* A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies","ALL","0 Months","18 Years",{"count":21,"type":22},250,"ESTIMATED","OBSERVATIONAL","The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.\n\nDevelop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.",[26,27],"Staging","Therapeutic Recommendations","RECRUITING","2026-02-27",{"date":31,"type":32},"2026-03-02","ACTUAL",{"date":34,"type":32},"2022-11-15",{"date":36,"type":22},"2030-12-31",{"name":38,"class":39},"French Africa Pediatric Oncology Group","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":48,"targetDuration":50,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":59},"100423472","recommendations-for-the-treatment-of-children-with-acute-lymphoblastic-leukemia-in-the-gfaop-100423472","NCT04794296","Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP","LALGFA2019","Inclusion Criteria:\n\nChildren 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2\n\n\\-\n\nExclusion Criteria:\n\nALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21",{"count":49,"type":22},500,"10 Years","The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G\u002FL or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.",[53],"Childhood ALL",{"date":31,"type":32},{"date":56,"type":32},"2021-11-15",{"date":36,"type":22},{"name":38,"class":39},3,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":77},"100395157","recommendations-for-the-treatment-of-children-with-burkitts-lymphoma-100395157","NCT04425421","Recommendations for the Treatment of Children With Burkitt's Lymphoma","GFALMB2019","Inclusion Criteria:\n\nClinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.\n\n\\-\n\nExclusion Criteria:\n\nNot a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.",{"count":68,"type":22},1000,"This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.",[71],"Burkitt Lymphoma",{"date":31,"type":32},{"date":74,"type":32},"2020-11-01",{"date":36,"type":22},{"name":38,"class":39},7,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":19,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":77},"100395008","therapeutic-recommendations-for-nephroblastoma-100395008","NCT04423484","Therapeutic Recommendations for Nephroblastoma","Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.","GFANEPHRO20","Inclusion Criteria:\n\nUnilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.\n\n.\n\nExclusion Criteria:\n\nBilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal","6 Months",{"count":68,"type":22},"The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.",[90],"Nephroblastoma",{"date":31,"type":32},{"date":93,"type":32},"2020-07-01",{"date":95,"type":22},"2030-12-30",{"name":38,"class":39},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":112,"locationsCount":77},"100395158","therapeutic-recommendations-for-the-treatment-of-children-with-a-retinoblastoma-100395158","NCT04425434","Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma","GFARB12019","Inclusion Criteria:\n\n* Unilateral intraocular Retinoblastoma (RB)\n* Unilateral extraocular intraorbital (RB)\n* Bilateral intraocular (RB)\n* bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.\n\nExclusion Criteria:\n\n* Externalized tumor mass\n* massive extension to optic nerve up to optical channeltumor\n* intracranial extension leptomeninges\n* cerebral parenchyma\n* extension to regional lymph nodes and\u002For remote metastases.\n* cerebrospinal fluid involvement.\n* Trilateral RB\n* Incapacity to followed the whole treatement.",{"count":105,"type":22},3000,"As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.",[108],"Retinoblastoma",{"date":31,"type":32},{"date":74,"type":32},{"date":36,"type":22},{"name":38,"class":39},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":19,"enrollmentInfo":122,"targetDuration":124,"studyType":23,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100347437","hospital-based-registry-of-childhood-cancer-in-pediatric-oncology-units-in-french-speaking-africa-100347437","NCT03803735","Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa","French African Pediatric Oncology Registry","RFAOP","Inclusion Criteria:\n\n1. Any child presenting at any one of the participating units for treatment\n2. Any child with any type of cancer\n3. Any child or adolescent less than 18 years of age.\n\nExclusion Criteria:\n\n1. No cancer found\n2. Age greater than 18 years -","1 Day",{"count":123,"type":22},10000,"12 Months","The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.\n\nCollecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.",[127],"Pediatric Cancer","2025-09-29",{"date":130,"type":32},"2025-10-03",{"date":132,"type":32},"2016-01-01",{"date":134,"type":22},"2030-12",{"name":38,"class":39},14,""]